Novartis | NOVN - Despesas De Vendas E Administração

Preço das Ações
121.52
Mudança Diária
0.16 0.13%
Mensal
-5.34%
Anual
23.25%
Q1 Previsão
118.31




Despesas De Vendas E Administração Alterar Data
AbbVie USD 3.89B 325M 2025-12
Alcon AG USD 901M 36M 2025-12
Amgen USD 1.94B 237M 2025-12
AstraZeneca USD 4.61B 4.46B 2025-12
Autolus Therapeutics Ltd USD 34.11M 6.16M 2025-09
Bayer EUR 4.05B 647M 2025-12
Biogen USD 545.2M 38.6M 2025-09
Bristol-Myers Squibb USD 2.18B 392M 2025-12
Eli Lilly USD 3.13B 391.3M 2025-12
Fresenius EUR 819M 143M 2025-12
Fresenius Medical Care EUR 785M 79.56M 2025-12
Galapagos EUR 44.42M 9.87M 2025-12
Genmab DKK 144M 18M 2025-06
Gilead Sciences USD 1.78B 425M 2025-12
GlaxoSmithKline GBP 2.68B 518M 2025-12
GRIFOLS EUR 275.3M 9.7M 2025-12
Hikma Pharmaceutical USD 288M 149M 2025-12
J&J USD 6.75B 831M 2025-12
Merck EUR 1.6B 136M 2025-12
Merck USD 2.85B 215M 2025-12
Novartis USD 3.31B 134M 2025-09
Novartis USD 3.3B 137M 2025-09
Novo Nordisk DKK 17.44B 1.41B 2025-12
Orion EUR 110.7M 26.1M 2025-12
Pfizer USD 4.08B 894M 2025-12
Philips EUR 1.31B 127M 2025-12
Recordati EUR 171.38M 15.6M 2025-09
Regeneron Pharmaceuticals USD 775M 117.2M 2025-12
Roche Holding CHF 7.28B 3.99B 2025-12
Sanofi EUR 2.75B 455M 2025-12
UCB EUR 1.29B 221M 2024-12